JPMorgan analyst Jessica Fye reinstated coverage of Mirum Pharmaceuticals with an Overweight rating and $37 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MIRM:
- Mirum reports new data from LIVMARLI and volixibat programs presented at meeting
- Mirum Pharmaceuticals initiated with an Overweight at Morgan Stanley
- Mirum Pharmaceuticals price target lowered to $60 from $63 at H.C. Wainwright
- Mirum Pharmaceuticals reports Q3 EPS (57c), consensus (65c)
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call